Top Lipidologist Blows Whistle: Big Pharma Invented ‘Cholesterol Myth’ to Sell New Generation of Drugs

For more than half a century, the public has been told that high cholesterol is the enemy of the heart. Doctors were instructed that the lower the number, the better — and pharmaceutical companies built an empire on that fear.

Now, a growing group of researchers says the story isn’t so simple. Among them is Dr. Uffe Ravnskov, a Swedish physician and internationally recognized lipid researcher whose career has focused on re-examining the science behind cholesterol and heart disease.

Ravnskov has spent decades analyzing data that he says exposes major gaps in the conventional narrative — and raises uncomfortable questions about how corporate profit influences medical policy.

A Lifelong Critic of the Cholesterol Hypothesis

Ravnskov first gained attention with his book The Cholesterol Myths, which argued that the evidence linking cholesterol to heart disease was less clear-cut than official guidelines suggested.

He pointed to long-term studies such as the Framingham Heart Study, whose later follow-ups found that people whose cholesterol levels dropped over time sometimes experienced higher mortality rates — an observation he believes deserved far more public discussion.

According to Ravnskov, medicine’s relentless focus on lowering cholesterol may have overshadowed other, more complex causes of cardiovascular disease such as inflammation, oxidative stress, and diet quality.

“That’s Not Health Care — That’s Marketing”

In interviews and writings, Ravnskov has accused the pharmaceutical industry of turning a nuanced scientific question into a marketing opportunity.

“Now doctors want you down to 150,” he has said. “Every time the numbers are lowered, millions more people suddenly ‘need’ drugs. That’s not health care — that’s marketing.”

With global statin sales exceeding $20 billion a year, critics argue the financial incentive to keep the cholesterol theory alive is enormous. They say each revision of “healthy” cholesterol targets expands the pool of potential customers — often with marginal, or even questionable, benefits for overall survival.

The Statin Debate

Statins undeniably lower LDL cholesterol, and for patients at very high risk of cardiovascular events, many studies show they can provide benefit. Yet skeptics contend that these benefits are sometimes overstated, particularly for healthy adults with no prior heart disease.

Some meta-analyses suggest that the absolute risk reduction in low-risk populations is small — perhaps translating into a few days or weeks of extended life expectancy rather than years.

Independent researchers like Ravnskov question whether the widespread prescription of statins to millions of otherwise healthy people truly represents evidence-based medicine or an industry-driven precaution.

Following the Money

Medical guidelines are often written by panels that include researchers with ties to drug manufacturers. Critics say this structural overlap creates a subtle bias toward pharmaceutical interventions. They call for greater transparency, more focus on non-drug approaches — diet, exercise, stress reduction — and a reassessment of whether “lower is always better” for cholesterol.

A Call for Open Debate

Ravnskov and like-minded colleagues emphasize that they are not anti-medicine but pro-science. They argue that honest debate and independent review are essential to public trust. Suppressing dissenting data, they warn, only deepens skepticism about mainstream health advice.

“The science of cholesterol is still evolving,” Ravnskov has written. “But the public deserves to know when that science has been shaped as much by marketing as by medicine.”